CNTF and Parkinson disease: The administration of neutralizing antibodies for CNTF significantly attenuated the hRheb(S16H)-induced neuroprotection in the MPP+-treated model of PD [Fig. 3B; p < 0.001 vs. contralateral controls, p = 0.010 vs. hRheb(S16H) + MPP+].